Subcutaneous immunoglobulin for patients with antibody deficiency.
This article provides an overview on the management of primary immunodeficiency, and discusses the pharmacokinetics of subcutaneous and intravenous immunoglobulin and the relationship between blood levels and therapeutic effects in both treatments. The article will further highlight both treatments' efficacy in preventing infections and the risk of systemic side effects with each treatment.
Helbert
Matthew
M
Department of Immunology, Manchester Royal Infirmary.
Farragher
Alex
A
D000279:Administration, Cutaneous; D000906:Antibodies / Q000191:economics / Q000276:immunology*; D003365:Costs and Cost Analysis; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000191:economics; D007153:Immunologic Deficiency Syndromes / Q000191:economics / Q000628:therapy*
D000906:Antibodies; D007136:Immunoglobulins